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Abstract 
Berberine-INF55 hybrids are a promising class of antibacterials that combine berberine and the 
NorA multidrug resistance (MDR) pump inhibitor INF55 (5-nitro-2-phenyindole) together in one 
molecule via a chemically stable linkage. Previous studies demonstrated the potential of these 
compounds for countering efflux-mediated antibacterial drug resistance but they didn’t establish 
whether the compounds function as originally intended; i.e. with the berberine moiety providing 
antibacterial activity and the attached INF55 component independently blocking MDR pumps, 
thereby enhancing the activity of berberine by reducing its efflux. We hypothesized that if the 
proposed mechanism is correct then hybrids carrying more potent INF55 pump inhibitor structures 
should show enhanced antibacterial effects relative to those bearing weaker inhibitors. Two INF55 
analogues showing graded reductions in NorA inhibitory activity compared to INF55 were 
identified and their corresponding berberine-INF55 hybrids carrying equivalent INF55 inhibitor 
structures synthesised. Multiple assays comparing the antibacterial effects of the hybrids and their 
corresponding berberine/INF55 analogue combinations showed that the three hybrids all show very 
similar activities, leading us to conclude that the antibacterial mechanism(s) of berberine-INF55 
hybrids is different from berberine/INF55 combinations. 
 
Introduction 
A promising strategy for countering efflux-mediated antibiotic resistance in bacteria is to co-
administer a small molecule multi-drug resistance (MDR) efflux pump inhibitor (EPI) in 
combination with an antibacterial.[1] In this strategy, the MDR inhibitor serves to limit efflux of the 
antibacterial and raise its intracellular concentrations above sub-lethal levels to enhance 
antibacterial potency. Potential clinical disadvantages of the approach, however, include the 
requirement for matching pharmacokinetic and physicochemical properties of two structurally 
unrelated molecules, along with other co-dosing challenges. One possible solution is to covalently 
link the MDR inhibitor and antibacterial components together into a single (non-cleavable) hybrid 
molecule.[2-4] Such hybrids carry the potential advantage of delivering equimolar quantities of the 
two agents to infection sites whilst avoiding the complications of multi-agent co-dosing.[5] 
In 2006 Bremner et al. reported the first such hybrid, termed SS14-O 1 (Fig. 1),[2] 
comprising the antibacterial alkaloid berberine substituted at its 13-position via a stable 2'-CH2 
linkage to 5-nitro-2-phenyindole 5 (INF55), a well-known inhibitor of the NorA MDR pump in 
Staphylococcus aureus.[6] In designing SS14-O 1 it was reasoned that the berberine moiety (a 
known substrate for NorA)[7] could show enhanced antibacterial effects (membrane activity and 
interactions with DNA)[8] as part of a hybrid due to higher intracellular concentrations arising 
through inhibition of NorA-mediated efflux by the appended INF55 5 component. SS14-O 1 was 
shown to accumulate in wild-type, norA-knockout and NorA overexpressing strains of S. aureus 
and showed higher antibacterial potency than berberine alone or berberine in combination with 
INF55 5.[2] A follow-up study explored the effects of varying the relative orientations of the 
berberine and INF55 components in hybrids by comparing the activities of isomers SS14-O 1, 
SS14-M 2 and SS14-P 3 (Fig. 1).[9] The three isomers showed remarkably similar minimum 
inhibitory concentrations (MICs) given their structural differences, which remained essentially 
unchanged across wild-type, norA-knockout, and NorA overexpressing S. aureus cells. The three 
isomers accumulated in S. aureus cells and showed identical abilities to block Enterococcus 
faecalis-mediated killing of the nematode Caenorhabditis elegans in a gastrointestinal infection 
model. A key conclusion from these studies was that berberine-INF55 hybrids are not substrates 
for NorA, although ethidium bromide uptake/efflux experiments suggested that these hybrids 
might block the NorA pump.[9] Another study exploring an SS14-O 1 analogue with an extended 
methylene ether linkage (4, Fig. 1) showed that this compound displays similar antibacterial 
activity to the other hybrids and that its activity remains consistent across S. aureus strains 
expressing varying levels of NorA.[10]  
 
N
O
O
OMe
OMe
R
X
13
R = 2'-substituted, X = Br, Cl
R = 3'-substituted, X = Cl
R = 4'-substituted, X = Cl
N
H
O2N
2' 3'
4'
R =
Berberine (R = H)
5
N
H
O2N
O
1
2
3
R = X = Br 4
SS14-O
SS14-M
SS14-P
AntibacterialNorA MDR pump inhibitor
(a)
Berberine-INF55 hybrid antibacterials
(b)
R1 = NO2,
R1 = H,
N
O
O
OMe
OMe
Cl
N
R1
R2
R2 = CH3
R2 = CH3
8
9
N
R2
R1
R1 = NO2, R
2 = H 5
6R1 = NO2, R
2 = CH3
INF55
R1 = H, R2 = CH3 7
2' 3'
4'
R1 = NO2,R
2 = H 3SS14-P
 
Fig. 1. (a) Berberine-INF55 hybrid antibacterials 1-4.[2,9,10] (b) INF55 (5-nitro-2-phenylindole) 5, 
N-Methyl-INF55 6 and N-Methyl-2-phenylindole 7 and their corresponding berberine-INF55 
hybrids 3, 8 and 9. 
 
 
While the above studies demonstrated the promising antibacterial properties of berberine-
INF55 hybrids, the observation that the hybrids do not appear to be substrates for NorA cast doubt 
on whether the hybrids function as originally intended; i.e. with the INF55 moiety serving to block 
NorA MDR pumps (and thus efflux) and the attached berberine moiety providing (enhanced) 
antibacterial action. In this current study we further explored whether the proposed mechanism of 
the hybrids was indeed underpinning their activity. Central to the study was the hypothesis that if 
the proposed mechanisms were at play then a direct correlation should exist between the ability of 
structurally distinct INF55-type MDR pump inhibitors to potentiate the antibacterial activity of 
berberine when co-administered and the activity of the corresponding berberine/INF55 hybrids. In 
other words, INF55-type MDR pump inhibitors that more strongly potentiate the antibacterial 
activity of berberine when co-administered should confer a higher level of antibacterial potency to 
the corresponding berberine-INF55 hybrids. 
Exploring this hypothesis required analogues of INF55 5 that: (1) showed a range of 
antibacterial potentiation effects when co-administered with berberine and (2) could be attached at 
the berberine 13-position to create hybrids differing only in the structure of the appended INF55 
moiety. Checkerboard assays (see below) identified N-Methyl-INF55 6 and N-methyl-2-
phenylindole 7 as suitable INF55 5 analogues (Fig. 1). This paper reports the synthesis and parallel 
evaluation of berberine/INF55 hybrids 3, 8 and 9, which incorporate INF55 5 and analogues 6 and 
7, respectively (Fig. 1), and their corresponding berberine/5,6,7 combinations, in multiple assays 
aimed at testing the above hypothesis. 
 
Chemistry 
The synthesis of INF55 5, analogues 6 and 7 and hybrids 3, 8 and 9 is outlined in Scheme 1. INF55 
5 was obtained in 91% yield via regioselective nitration of 2-phenyl indole 10 using the literature 
method.[11]  N-Methyl-INF55 6 was prepared in 80% yield by stirring INF55 5 for two hours at 
room temperature with K2CO3 and CH3I in anhydrous DMF. N-Methyl-2-phenylindole 7 was 
prepared in 80% yield by stirring 2-phenylindole 10 for 2 hours in anhydrous THF at room 
temperature with NaH and CH3I. 
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Scheme 1. Reagents and conditions: (a) NaH, CH3I, THF, 80%; (b) NaNO3, H2SO4, -10 °C, 
70%;[11] (c) K2CO3, CH3I, DMF, 80%; (d) PdCl2, 1,4-dioxane, methyl 4-iodobenzoate, 100 °C, 
84%; (e) TFA:CH2Cl2 (1:1), 79%; (f) NaNO3, H2SO4, -10 °C;
[12] (g) LiBH4, THF, 40 °C;
[12] (h) 
CBr4, PPh3, THF:Et2O (1:1);
[12] (i) NaI (10 mol %), CH3CN, 70 
oC, anion exchange 40%; (j) CH3I, 
K2CO3, DMF, anion exchange, 75%; (k) PdCl2, methyl 4-iodobenzoate, 1,4-dioxane, 100 °C, 75%; 
(l) LiAlH4, THF, 40 °C, 85%; (m) CCl4:CH2Cl2 (1:1), PPh3, ~65% (crude); (n) NaI (10 mol %), 
CH3CN, 70 
oC, anion exchange, 40%. 
Our previously reported synthesis of SS14-P 3[12] involved reacting 8-
allyldihydroberberine[13] in the final step with the key benzylic bromide intermediate 16; prepared 
via functional group manipulations with the precursor methyl ester 13. In the prior work, 13 was 
synthesised directly from indole and methyl-4-iodobenzoate in a single step using the rhodium 
(III)-catalysed indole C2-arylation method reported by Sames et al.[14] While this reaction 
invariably provides some 13, the yields are always low (max 28%) and the reaction outcomes 
unpredictable. A more robust Stille coupling-based approach was therefore developed to install the 
functionalised 4-carboxymethyl aryl substituent at the indole C2-position. Stille coupling of N-
Boc-2-tributylstannylindole 11 (prepared in two steps via the literature method)[15] with methyl-4-
iodobenzoate using PdCl2 in refluxing 1,4-dioxane gave 12 in 84% yield. Boc-deprotection of 12 
using CH2Cl2:TFA (1:1) subsequently afforded the NH-indole 13 in 79% yield. While the new 
route to 13 is longer, it is simple to carry out and reproducible on a multi-gram scale. The key 
intermediate 16 was then obtained from 13 using our reported 3-step nitration, reduction, 
bromination sequence.[12]    
A new reaction for producing SS14-P 3 was developed wherein bromide 16 was coupled to 
8-acetonyldihydroberberine 17[16] instead of 8-allyldihydroberberine, as had been performed 
previously.[12] Catalytic Finkelstein conversion of bromide 16 in situ to the iodide with 10 mol% 
NaI in CH3CN at 70 
oC in the presence of 8-acetonyldihydroberberine 17 gave SS14-P 3 in 40% 
yield. Preparative RP-HPLC purification in the presence of 0.1% HCl initially provided mixed Cl-
/Br-/I- salts that were subsequently converted to pure Cl- salts of 3 by anion exchange (Scheme 1). 
Although the new procedure didn’t provide higher yields of SS14-P 3 it was more reproducible than 
the 8-allyldihydroberberine method,[12] which for unknown reasons sometimes failed to yield any 3. 
SS14-P 3 was converted to the N-methylated hybrid 8 in 75% yield by reaction with excess 
CH3I and K2CO3 in DMF at room temperature. The mixture of Cl
-/I- salts initially obtained after 
silica gel column chromatography (CH3CN:EtOAc:MeOH, 1:1:0.5) was converted to the pure Cl
-
 
salt 8 by anion exchange. Hybrid 9 was prepared by reacting 8-acetonyldihydroberberine 17 with 
the benzylic chloride intermediate 21, which was synthesised in 3 steps from (N-methylindol-2-
yl)tributylstannane 18 (prepared by the literature method).[15] In the first step, PdCl2 catalysed Stille 
coupling of 18 with methyl-4-iodobenzoate provided 19 in 75% yield. 
Reduction of the methyl ester 19 with LiAlH4 (added portion wise) in anhydrous THF with 
gentle heating at 40 oC gave the benzylic alcohol 20 in 85% yield. Chloride 21 was prepared by 
stirring 20 in CCl4:CH2Cl2 (1:1) for 10 min before adding PPh3 (4 eq). TLC analysis 
(EtOAc:hexane, 8.5:1.5) was used to monitor the reaction and upon completion the mixture was 
quickly filtered through a plug of neutral alumina and washed with CH2Cl2. The filtrates were 
concentrated in vacuo and the residue triturated with pentane. The crude 21 was used immediately 
due to its instability and was unable to be fully characterised. Reaction of crude 21 with 8-
acetonyldihydroberberine 17 in the presence of 10 mol% NaI in CH3CN at 70 
oC provided hybrid 9 
in 40% yield after preparative RP-HPLC and anion exchange. 
 
Checkerboard assays in S. aureus strains with varying NorA expression levels 
Preliminary antibacterial checkerboard assays[2] were performed using 8325-4 wild-type, K1758 
norA-knockout and K2378 NorA overexpressing S. aureus cells with berberine/5-7 combinations 
to confirm their suitability as INF55-based NorA EPIs for use in this study (Fig. 2). Complete 
growth inhibition was observed in all three S. aureus strains with INF55 5 at 1.25 g/mL and 
berberine present at concentrations below 20 g/mL. Analogues 6 and 7 at 1.25 g/mL did not 
inhibit growth of 8325-4 and K1758 cells in the presence of berberine at the highest concentrations 
tested (125 µg/mL or 30 µg/mL). Growth inhibition of K2378 cells was observed with 6 and 7 at 
1.25 g/mL, but only with berberine present at 125 g/mL. N-Me-INF55 6 did not inhibit 8325-4 
growth at the highest concentration tested (80 g/mL) with 125 g/mL berberine present. The 
results are consistent with the following rank order of berberine antibacterial potentiation effects 
for the compounds: 5 > 7 > 6. The graded reductions in activity confirmed 5-7 were a suitable 
series of INF55-based NorA EPIs for testing the above-stated hypothesis. 
 
Fig. 2. Checkerboard assays comparing potentiation of berberine’s antibacterial effects by INF55 5 
(♦), 6 (■) and 7 (▲) against (a) 8325-4 wild-type, (b) K1758 norA-knockout and (c) K2378 NorA 
overexpressing S. aureus cells. Compounds 5-7 showed no antibacterial effects against these 
strains when administered alone at concentrations below or equal to 80 g/mL. MICs for berberine 
alone against 8325-4, K1758 and 2378 were 125 g/mL, 30 g/mL and 250 g/mL, respectively.[2] 
 
Antibacterial activities against S. aureus strains 
The checkerboard experiments indicated that potentiation of berberine’s activity by the three 
INF55-based NorA EPIs 5-7 decreases in the order 5 > 7 > 6 against 8325-4 wild-type, K1758 
norA-knockout and K2378 NorA overexpressing S. aureus cells. Accordingly, if the above-stated 
hypothesis were correct then their respective hybrids 3, 8 and 9 should show antibacterial potencies 
in the order 3 > 9 > 8 against these cells, assuming no synergistic or antagonistic action between 
the two components when joined. The MICs for complete inhibition of bacterial growth was 
measured for hybrids 3, 8 and 9 against the S. aureus panel with vancomycin included as a control 
(Table 1). All three hybrids showed identical MICs (0.78 g/mL) against 8325-4 and K2378 and 2-
fold higher potencies (0.39 g/mL) against K1758. The MIC of vancomycin was 1 g/mL against 
the three strains. Consistent MICs (< 2-fold difference) for 3, 8 and 9 confirmed that they are all 
poor substrates for NorA. Lack of variation in MICs was a feature observed previously with 
hybrids 1-4 and indicates that the molecular target(s) of berberine-INF55 hybrids is(are) tolerant of 
structural variations within the INF55 portion. However, unvarying MICs for hybrids 3, 8 and 9 is 
not consistent with the stated hypothesis, since if correct, the MICs would have increased in the 
order 3 < 9 < 8. 
 
S. aureus 
strains Compound 
MIC 
(μg/ml) 
8325-4 
3 0.78 
8 0.78 
9 0.78 
vancomycin 1 
K1758 
3 0.39 
8 0.39 
9 0.39 
vancomycin 1 
K2378 
3 0.78 
8 0.78 
9 0.78 
vancomycin 1 
Table 1. MICs of hybrids 3, 8, and 9 and vancomycin (control) against wild-type (8325-4), norA-
knockout (K1758) and NorA overexpressing (K2378) S. aureus strains. 
 
Uptake into S.aureus cells 
Uptake of hybrids 3, 8 and 9, berberine and berberine in the presence of INF55 5 and analogues 6, 
7 into 8325-4, K1758 and K2378 S. aureus cells was compared using our previously reported 
fluorescence-based method.[9] The interaction of berberine or hybrids with DNA upon entering 
cells causes an increase in fluorescence at 517 nm (excitation at 355 nm), while expulsion of these 
compounds from cells via efflux leads to lower fluorescence intensities, thus providing a 
qualitative measure of compound efflux susceptibility. Fig. 3 indicates that berberine at 3 M alone 
does not accumulate significantly in any of the S. aureus strains, consistent with its high efflux 
susceptibility. Lack of berberine uptake into norA-knockout strain K1758 suggests that pumps 
other than NorA must also contribute to its efflux. Uptake of berberine did not increase in any of 
the strains in the presence of equimolar 7 and only small increases were observed withcompounds 
5 and 6 present. These results suggest that NorA inhibition by INF55 5 and analogues 6, 7 has only 
a minor effect on berberine accumulation, possibly due to the countering effects of other pumps not 
affected by these inhibitors. Nevertheless, the ability of INF55 analogues (5 in particular) to 
potentiate the antibacterial activity of berberine (Fig. 2) against the same S. aureus strains suggests 
that this seemingly slight effect on berberine uptake is sufficient to enhance antibacterial effects. 
Significantly larger increases in fluorescence were observed with hybrids 3, 8 and 9 at the 
same concentrations (3 M), indicating that they are taken up to a greater extent in these cells than 
berberine or berberine in the presence 5-7 (Fig.3). For these experiments it was necessary to 
demonstrate that the high fluorescence observed with hybrids was due to increased cellular uptake 
and not increased fluorescence intensity of hybrid/DNA complex(es) relative to berberine/DNA 
complex(es). Cell-free control experiments comparing fluorescence upon binding to calf thymus 
DNA (CT-DNA)[17] of hybrids 3, 8, 9, berberine and berberine in the presence of 5, 6 and 7 showed 
that complexes formed between the three hybrids and CT-DNA exhibited significantly less 
fluorescence than berberine/DNA complexes (data not shown), supporting the conclusion that 
higher intracellular uptake of 3, 8 and 9 had occurred relative to berberine alone or berberine in 
mixtures with 5-7. 
Uptake of each hybrid was unchanged across the three strains, consistent with the 
compounds not being substrates for NorA (in agreement with the MIC data, Table 1). While the 
uptake data confirmed that 3, 8 and 9 accumulate in these cells, there was no evidence to support 
that incorporation of higher potency INF55-based EPIs leads to increased uptake. If this were true, 
uptake of the hybrids should have increased in the order 8 < 9 < 3 (based on the checkerboard data 
in Fig. 2). Hybrids 8 and 9 appeared to show identical uptake in all strains that was greater than 
that of 3 in spite of 3 containing the most potent NorA EPI 5. 
  
 
Fig. 3. Uptake of hybrids 3 (◊), 8 (□), 9 (∆), berberine (●) and  berberine in the presence of 5 (♦),  6 
(■) and 7 (▲) into (a) 8325-4 wild-type, (b) K1758 norA-knockout and (c) K2378 NorA 
overexpressing S. aureus cells. Uptake was measured by monitoring fluorescence at 517 nm 
(excitation at 355 nm) and is expressed in arbitrary fluorescence units A.U. All compounds were 
present at 3 M in 1% DMSO solutions. 
Antibacterial activity and checkerboard assays with methicillin-resistant S. aureus (MRSA) 
and E. faecalis 
Bacterial 
strains Compound 
MIC 
(μg/ml) 
MRSA 
MW2 
berberine 50 
5 > 100 
6 > 100 
7 > 100 
3 3.13 
8 3.13 
9 < 1.56 
vancomycin < 1.56 
E. faecalis 
MMH594 
berberine > 100 
5 > 100 
6 > 100 
7 > 100 
3 3.13 
8 3.13 
9 3.13 
vancomycin < 1.56 
Table 2. MICs of INF55 5, analogues 6 and 7, hybrids 3, 8 and 9 and vancomycin (control) in 
liquid cultures of MRSA MW2 and E. faecalis MMH594. 
 
 The above-stated hypothesis was further tested by comparing the curative effects of the 
hybrids in two C. elegans live infection models. In these models, C. elegans is infected with 
methicillin-resistant S. aureus (strain MW2) or E. faecalis (MMH594) and worm survival is 
measured relative to controls. Before performing these experiments it was necessary to measure the 
MICs of each compound against S. aureus MW2 and E. faecalis MMH594 cells in liquid cultures 
(Table 2). Berberine showed an MIC of 50 µg/mL against MRSA MW2 and lower potency (MIC 
100 µg/mL) against E. faecalis MMH594. All three EPIs 5-7 showed no activity against either 
strain when administered alone at < 100 µg/mL. Hybrids 3, 8 and 9 on the other hand, all showed 
robust but virtually identical activities (MICs 1.56 – 3.13 g/mL). These data once again conflicted 
with the hypothesis since MICs for 3, 8 and 9 should have increased in the order 3 < 9 < 8 if it were 
supported. 
 
Checkerboard assays were used to compare the berberine potentiation effects of 5-7 in MW2 
and MMH594 cells (Fig. 4). As expected, INF55 5 was the most potent EPI with 25 µg/mL and 
concentrations of berberine below 10 µg/mL strongly inhibiting MW2. EPIs 6 and 7 required > 50 
µg/mL to show any effect. The three EPIs were notably less effective against MMH594, where 
concentrations of 5 greater than 50 µg/mL and higher concentrations of berberine were required to 
produce an effect. Compound 7 showed only weak activity at 100 µg/mL and required higher 
concentrations of berberine. Compound 6 showed no potentiation at the highest concentration 
tested. The berberine potentiation activity of the EPIs thus decreased in the order 5 > 7 > 6 against 
MW2 and MMH594, in agreement with the order observed with S. aureus strains 8325-4, K1758 
and K2378 (Fig. 2). These data supported 5-7 (and their respective hybrids 3, 8 and 9) being 
suitable compounds for testing our berberine/INF55 hybrid mechanism hypothesis in the C. elegans 
live infection models. 
 
 
Fig. 4. Checkerboard assays comparing the potentiation of berberine’s antibacterial effects by 
INF55 5 (♦) and analogues 6 (■) and 7 (▲) against (a) MRSA MW2 and (b) E. faecalis MMH594. 
 
C. elegans/MRSA and C. elegans/E. faecalis live infection models 
The C. elegans/MRSA live infection model measures worm survival after infection with MRSA 
MW2.[18] In the absence of antimicrobials the worms die but they can be rescued by treatment with 
vancomycin (Fig. 5(a), Vanc 20 g/mL). Increasing concentrations (0-200 g/mL) of berberine, 
EPIs 5-7 and hybrids 3, 8 and 9 were used to investigate their effects on MRSA MW2-infected 
worm survival. Berberine was found to increase survival relative to the 1% DMSO control at 
concentrations above 50 µg/mL, consistent with its MIC (50 g/mL) against this species (Table 2). 
None of the EPIs showed any curative effects when tested alone. Hybrids 3, 8 and 9, however, all 
showed robust curative effects, but there were no clear differences between their potencies. 
Checkerboard survival assays where berberine was co-administered with EPIs 5-7 to worms 
infected with MRSA were attempted but reproducible data were unable to be obtained, possibly due 
to the toxicity of INF55-based EPIs to worms.[2] 
 
 
 
 
 
Fig. 5. Survival (%) of C. elegans worms infected with (a) MRSA MW2 and (b) E. faecalis 
MMH594 following treatment with increasing concentrations of berberine, INF55 5 and analogues 
6, 7 and hybrids 3, 8, and 9. Vancomycin (Vanc, 20 g/mL) and tetracycline (Tet, 20 g/mL) were 
included as positive controls in the MRSA and E. faecalis experiments, respectively, and 1% 
DMSO as a negative control. Compound concentrations are in g/mL. All assay solutions contained 
1% DMSO. 
In the C. elegans/E. faecalis live infection model[9] worms are infected with E. faecalis 
MMH594 and their survival monitored over several days. In the absence of antimicrobials the 
worms die but they can be rescued with tetracycline (Fig. 5(b), Tet 20 g/mL). Berberine and EPIs 
5-7 alone showed no effect on survival over the concentration range tested (0-200 µg/mL). The lack 
of activity of berberine against E. faecalis MMH594 was consistent with its low in vitro potency 
against this organism (MIC > 100 µg/mL, Table 2). The three hybrids 3, 8 and 9 all showed strong 
rescuing effects at concentrations above 6.25µg/mL, but once again there were no clear differences 
between their potencies. As with the MRSA MW2 model, checkerboard experiments were 
attempted with berberine/ 5-7 combinations but reproducible data were unable to be obtained. 
 
Concluding Remarks 
This study aimed to test the hypothesis that berberine-INF55 hybrids elicit their antibacterial effects 
through the combined activities of their two functionally distinct components, with the berberine 
moiety acting to kill bacterial cells and the INF55 portion serving to block NorA-mediated efflux. 
Checkerboard assays with three S. aureus strains varying in NorA expression levels, along with 
MRSA MW2 and E. faecalis MMH594 strains, established that INF55 analogues 6 and 7 show 
graded reductions in their berberine potentiation potencies relative to 5, thus making them suitable 
compounds for testing the hypothesis. The three EPIs and their corresponding hybrids 3, 8 and 9 
were synthesised using a mix of literature and newly developed chemistry. 
The three hybrids showed strong antibacterial activity (measured as MICs) against all strains 
tested but the activity did not vary between the compounds, a result inconsistent with the 
hypothesis. Uptake of the three hybrids into S. aureus cells was confirmed using fluorescence-based 
cell assays but again the lack of variation in uptake did not support the hypothesis. The C. elegans 
MRSA and E. faecalis live infection experiments clearly demonstrated the robust curative effects of 
the hybrids, with worm survival also establishing that the compounds show low toxicity.  However, 
failure to observe significant differences between their activities was further evidence that the 
hypothesis was not supported. We conclude from this work that the mechanism(s) of antibacterial 
action of berberine/INF55 hybrids must be different from the mechanisms at play when berberine is 
co-administered with INF55-based EPIs. Further studies aimed at unravelling the true mechanism 
of action of this interesting class of antibacterials are therefore warranted. 
 
Experimental 
Chemistry 
THF and diethyl ether were dried over sodium and DMF and CH3CN was dried over 4 Å molecular 
sieves prior to use. 2-Phenylindole 10, CH3I, Sn(Bu)3Cl, n-butyllithium, PdCl2, CBr4, PPh3,LiAlH4, 
LiBH4 and IRA-904 quaternary ammonium Cl
- anion exchange resin were purchased from Sigma 
Aldrich. 4-Iodomethylbenzoate was synthesised by MeOH/H2SO4(cat) esterification of 4-
iodobenzoic acid, which was purchased from Matrix scientific. Analytical thin layer 
chromatography (TLC) was carried out using Merck 0.2 mm silica gel 60 F254 coated aluminium 
plates. Compounds were visualised by UV absorption (λ 254 nm) and/or staining with cerium 
ammonium molybdate. Column chromatography was performed using Merck silica gel 60 (230-400 
mesh). Low resolution electrospray ionisation mass spectra (ESI-MS) were obtained on a 
micromass Z-path (LCZ) spectrometer. Electron impact high resolution mass spectra (HRMS) were 
obtained on a Fisions/VG Autospec spectrometer using perfluorokerosene as internal standard. ESI 
HRMS were obtained on a Waters QT Ultima spectrometer using polyethylene glycol or 
polypropylene glycol as internal standard. 1H, 13C NMR experiments were performed using a 
Varian Mercury 300 MHz, Varian Inova 500 MHz or Varian Premium Shielded 500 MHz 
spectrometer at 25 oC. Chemical shifts are reported as δ (ppm) relative to internal TMS (or solvent 
where indicated). The abbreviations s = singlet, d = doublet, appt = apparent triplet, t = triplet, q = 
quadruplet, m = multiplet and bs = broad singlet are used throughout. RP-HPLC purifcations of 
hybrids 3 and 9 were performed using gradient elutions with solvents A (100% H2O, 0.1% HCl) 
and B (90% CH3CN, 10% H2O, 0.1% HCl) on a Sunfire 
TM Prep C18 OBDTM (5µM) steel jacketed 
column run at 30 mL.min-1 and detection at 254 nm. Analytical HPLC analyses were performed 
using a Shimadzu CLASS-LC10 VP system using gradient elutions with solvent A and B on a 
Phenomenex Luna µM C18 column run at 1mL.min-1 with detection at 254 nm. 
 
9,10-dimethoxy-13-(4-(5-nitro-1H-indol-2-yl)benzyl)-5,6-dihydro-[1,3]diolo[4,5-]isoquinolino[3,2-
a]isoquinolin-7-ium chloride 3 
To a stirred solution of key bromide 16 (100 mg, 0.30 mmol) in anhydrous CH3CN (10 mL) was 
added sodium iodide (49 mg, 0.33mmol) and the mixture stirred for 1 h at 70 oC. 8-Acetonyl 
dehydroberberine 17 (118.8 mg, 0.30 mmol) was then added and stirring continued at 70 oC for 
another 3-4 h. The reaction was monitored by TLC (MeOH:CHCl3, 1:9 or EtOAc:hexane, 1:4) and 
ESI-MS. After completion, the reaction was diluted with CH3CN (5 mL) and the product adsorbed 
onto silica gel via evaporation of the solvent. Purification was performed using column 
chromatography (EtOAc:CH3CN:hexane, 1:1:1) initially followed by (EtOAc:CH3CN:MeOH, 
1:1:0.3) to afford semi pure 3. Further purification was carried out using RP-HPLC (gradient from 
A 0% to 100% B over 30 min, Rt  = 18.8 min). Fractions containing the product were combined and 
concentrated by freeze-drying. The salt mixture obtained was stirred with IRA-904 quaternary 
ammonium Cl- anion exchange resin in MeOH (5 mL) at rt for 1 h. Filtration and concentration 
yielded pure 3 as a yellow amorphous solid. (75 mg, 40%). mp 218-220 °C (decomp);1HNMR (500 
MHz, DMF-d6): δ 3.26 (s, 2H), 4.03 (s, 3H), 4.11 (s, 3H), 4.84 (s, 2H), 5.15 (bs, 2H), 6.06 (s, 2H), 
7.04 (s, 1H), 7.11  (s, 1H), 7.17 (s, 1H), 7.32 (d, J = 7.5 Hz, 2H), 7.62 (d, J = 9.0 Hz, 1H), 7.81-7.93 
(m, 3H), 8.07 (m, 2H), 8.46 (s, 1H), 10.1 (s, 1H), 13.05 (s, 1H); 13C NMR (125 MHz, DMF-d6): δ 
28.3, 36.3, 57.4, 58.1, 62.5, 101.3, 103.1, 109.1, 112.4, 117.4, 121.2, 122.4, 122.5, 126.8, 127.0, 
128.9, 129.5, 130.8, 131.0, 133.9, 135.0, 138.4, 140.3, 141.6, 142.0, 142.1, 145.4, 146.2, 147.5, 
150.4, 151.2, ESI-MS m/z Calc for C35H28N3O6
+ 586.1973; observed 586.1997. 
1-Methyl-5-nitro-2-phenyl-1H-indole 6 
To a stirred solution of INF55 5 (1g, 4.2 mmol) in anhydrous DMF  (10 mL) was added oven dried 
K2CO3 (1.74 g, 12.6 mmol) and stirred for 15-20 min at rt. Methyl iodide (0.8 mL, 12.6 mmol) in 
DMF (5 mL) was then added dropwise at rt and stirred for 1-2 h. Progress of the reaction was 
monitored by TLC (EtOAc:Hexane, 1:4). The reaction mixture was diluted with water and extracted 
with EtOAc (3 x 10 mL), the organic layer was washed with water and brine and dried over 
anhydrous Na2SO4 before concentrating in vacuo to afford 6 as a yellow solid (847 mg, 80%). mp 
175-178 oC; 1H NMR (300 MHz, CDCl3): δ 3.80 (s, 3H), 6.71 (s, 1H), 7.37 (d, J = 6.0 Hz, 1H), 
7.48-7.51 (m, 5H), 8.14 (d, J = 6.0 Hz, 1H), 8.58 (s, 1H); 13C NMR (75 MHz, CDCl3): δ 31.9, 
103.7, 109.4, 117.2, 117.5, 127.0, 128.7, 129.3, 131.4, 140.9, 141.8, 144.7. ESI-MS m/z Calc. for 
C15H13N2O2 [M+H
+] 253.0977; observed 253.0970. 
 
1-Methyl-2-phenyl-1H-indole 7 
To a stirred solution of 2-phenylindole 5 (1.0 g, 5.2 mmol) in anhydrous THF (10 mL) was added 
sodium hydride (372 mg, 15.5 mmol) and the reaction was stirred for 15 min at rt. Methyl iodide 
(2.20 g, 15.5 mmol) in anhydrous THF (10 mL) was added dropwise to the reaction mixture and 
stirred for 2 h. The reaction was monitored by TLC (EtOAc:Hexane, 1:9). The reaction mixture was 
quenched with saturated sodium sulphate and extracted with EtOAc (3 x 10 mL). The organic layer 
was separated, dried over anhydrous MgSO4 and concentrated in vacuo to afford 7 as a white solid 
(857 mg, 80%). mp 110-112 oC; 1H NMR (500 MHz, CDCl3): δ 3.86 (s, 3H), 6.54 (s, 1H), 7.12 (t, J 
= 8.0 Hz, 1H), 7.22  (t, J = 7.0 Hz, 1H), 7.30-7.36 (m, 2H), 7.40-7.48(m, 4H), 7.61 (d, J = 7.5 Hz, 
1H); 13C NMR (125 MHz, CDCl3): δ 31.1, 101.7, 109.6, 119.2, 120.5, 121.7, 127.8, 128.0, 128.5, 
129.4, 132.8, 138.4, 141.6; ESI-MS m/z Calc for C15H14N [M+H
+] 208.1126; observed 208.1126. 
 
 
9,10-dimethoxy-13-(4-(1-methyl-5-nitro-1H-indol-2-yl)benzyl)-5,6-dihydro-[1,3]dioxolo[4,5-
g]isoquinolino[3,2-a]isoquinolin-7-ium chloride 8 
To a stirred solution of hybrid 3 (70 mg, 1.1 mmol) in anhydrous DMF (5 mL) under Ar was added 
oven-dried K2CO3 (464 mg, 3.4 mmol) and the mixture was stirred for 15 min. Methyl iodide (0.21 
mL, 3.4 mmol) in DMF (2 mL) was added dropwise to the reaction and stirring continued for a 
further 1-2 h. Upon complete consumption of the starting material (ESI-MS) the mixture was 
concentrated in vacuo and the residue purified by silica gel flash column chromatography 
(CH3CN:EtOAc:MeOH, 1:1:0.5) to yield mixed Cl
-/I- salts. The salt mixture was stirred with IRA-
904 quaternary ammonium Cl- anion exchange resin in MeOH (5 mL) at rt for 1 h. After filtration 
and concentration the title compound 8 was obtained as a yellow amorphous solid (53.3 mg, 75%). 
mp 208-212 °C (decomp); 1H NMR (500 MHz, DMF-d6): δ 3.34 (s, 2H), 3.91 (s, 3H), 4.15 (s, 3H), 
4.21 (s, 3H), 5.00 (s, 2H), 5.18 (bs, 2H), 6.17 (s, 2H), 6.92 (s, 1H), 7.16 (s, 1H), 7.29 (s, 1H), 7.48 
(d, J = 6.5 Hz, 2H), 7.71 (d, J = 7.5 Hz, 2H), 7.75 (d, J = 8.5 Hz, 1H), 8.01 (m, 1H), 8.11 (d, J = 8.5 
Hz,1H), 8.18 (d, J = 9.0 Hz,1H), 8.59 (s, 1H), 10.40 (s, 1H); 13C NMR (125 MHz, DMF-d6): δ 28.3, 
32.2, 36.2, 57.4, 58.0, 62.6, 103.1, 104.4, 109.1, 109.2, 111.2, 117.3, 117.6, 121.1, 122.5, 122.5, 
126.8, 127.6, 129.4, 130.6, 130.9, 133.9, 135.2, 138.5, 140.9, 141.9, 142.2, 145.1, 145.6, 146.8, 
147.6, 150.4, 151.3; ESI-MS m/z Calc for C36H30N3O6 [M-Cl
-] 600.2129; observed 600.2122. 
 
9,10-dimethoxy-13-(4-(1-methyl-1H-indol-2-yl)benzyl)-5,6-dihydro-[1,3]dioxolo[4,5-
g]isoquinolino[3,2-a]isoquinolin-7-ium chloride 9 
To a solution of the crude chloride 21 (128  mg, 0.5 mmol) in anhydrous CH3CN (10 mL) was 
added sodium iodide (12.7 mg, 0.53 mmol) and the reaction was stirred for 1 h at 70 oC. 8-
acetonyldihydroberberine 17 (196.8 mg, 0.501mmol) was then added and stirring continued for 
another 3-4 h at 70 oC. The reaction was monitored by TLC (EtOAc:Hexane, 1:4) to observe 
consumption of the chloride, and also by ESI-MS. Upon completion of the reaction the mixture was 
purified by silica gel column chromatography using EtOAC:CH3CN:hexane (1:1:2) followed by 
EtOAc:CH3CN:MeOH (1:1:0.1). The semi-pure material was further purified by preparative RP-
HPLC using a gradient from 0% A to 100% B over 30 min (Rt = 21.5 min). The fractions 
containing pure product were pooled and concentrated by freeze-drying to yield 9 as a yellow solid 
(118 mg, 40%). mp 186-189 oC; 1H NMR (500 MHz, DMF-d6): δ 3.37 (s, 2H), 3.83 (s, 3H), 4.15  
(s, 3H), 4.23 (s, 3H), 5.01 (s, 2H), 5.22 (bs, 2H), 6.20 (s, 2H), 6.63 (s, 1H), 7.10 (appt, J = 7.5 Hz, 
1H), 7.20-7.25 (m, 3H), 7.48 (d, J = 7.5 Hz, 2H),  7.53 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H), 
7.69 (d,  J = 8.0 Hz, 2H), 8.04 (d, J = 7.5 Hz, 1H), 8.22 (d, J = 7.5 Hz, 1H) 9.42 (s, 1H); 13C NMR 
(125 MHz, DMF-d6): δ 28.3, 31.5, 36.2, 57.4, 58.2, 62.6, 102.1, 103.1, 109.1, 109.2, 110.6, 120.2, 
120.8, 121.1, 122.2, 122.4, 122.5, 126.8, 128.6, 129.2, 130.4, 131.1, 131.9, 134.0, 135.1, 138.5, 
139.3, 139.9, 141.4, 145.5, 146.5, 147.6, 150.4, 151.2; ESI-MS m/z Calc. for C36H31N2O4+ [M-Cl
-] 
555.2278; observed 555.2289. 
 
Tert-butyl-2-(4-(methoxycarbonyl)phenyl)-1H-indole-1-carboxylate 12 
To a stirred solution of 11 (5 g, 9.9 mmol) in anhydrous 1,4-dioxane (50 mL) was added 4-
iodomethylbenzoate (2.04 g, 7.78 mmol), palladium(II) chloride (43 mg, 0.24 mmol) and the 
reaction mixture was purged with nitrogen for 15 min. The reaction mixture was then heated to 100 
oC and stirred for one 1h while monitoring by TLC (EtOAc:Hexane, 1:9). The reaction mixture was 
cooled, diluted with EtOAc (100 mL) and stirred over 15% aqueous potassium fluoride (300 mL) 
for 15 min. The precipitate was removed by filtration and washed well with EtOAc (200 mL). The 
organic layer was separated, washed with water and brine, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by silica gel column chromatography 
(EtOAc:Hexane, 1.5:8.5) to afford 12 as a white semi-solid (2.3 g, 84%). mp 79-83 oC; 1H NMR 
(500 MHz, CDCl3): δ 1.32 (s, 9H), 3.94 (s, 3H), 6.6 (s, 3H), 7.2 (appt, J = 7.5 Hz, 1H), 7.35 (appt, J 
= 7.5 Hz, 1H), 7.50 (d, J = 7.5 Hz, 2H), 7.56 (d, J = 7.5 Hz, 1H), 8.07 (d, J = 7.5 Hz, 2H), 8.21 (d, J 
= 8.5 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ 27.6, 52.1, 83.8, 110.7, 115.2, 123.4, 125.1, 128.3, 
128.8, 129.0, 129.2, 137.9, 139.4, 149.9, 166.86. ESI-MS m/z Calc. for C21H21NNaO4 [M+Na
+] 
374.1368, found 374.1368. 
 
Methyl 4-(1H-indol-2-yl)benzoate 13 
To a stirred solution of 12 (2.3 g, 6.6 mmol) in anhydrous CH2Cl2 (7 mL) was added trifluoroacetic 
acid (7 mL) and the reaction mixture was stirred for 1-2 h. The mixture was concentrated in vacuo 
and the residue redissolved in ethyl acetate (100 mL). The EtOAc layer was washed with water and 
brine and dried over anhydrous Na2SO4 before concentrating in vacuo. The residue was purified by 
flash column chromatography (EtOAc:Hexane, 1:2) to afford 13 as an off-white crystalline solid 
(1.3 g, 79%). mp 204-205 °C; 1H NMR (500 MHz, CD3COCD3): δ 3.90 (s, 3H); 7.029-7.059 (m, 
2H), 7.14 (appt,  J = 7.0 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.96 (d, J = 8.5 
Hz, 2H), 8.05 (d, J = 8.5 Hz, 2H), 11.01 (bs, 1HUU); 13C NMR (125 MHz, CD3COCD3): δ 52.2, 101.8, 
112.2, 120.6, 121.4, 123.3, 125.6, 129.3, 129.9, 130.8, 137.3, 137.8, 138. 8, 166.9. ESI-MS m/z 
Calc for C16H14NO2 [M+H
+] requires 252.1025; found 252.1014. 
 
Methyl 4-(1-methyl-1H-indol-2-yl)benzoate 19 
A stirring solution of (N-methylindol-2-yl)tributylstannane 18 (5.0 g, 11.9 mmol) in anhydrous THF 
was charged with methyl-4-iodobenzoate (2.18 g, 8.3 mmol) and PdCl2 (97.6 mg, 0.832 mmol). The 
reaction mixture was purged with nitrogen for 30 min and then heated at reflux for 3-4 h with 
monitoring by TLC (EtOAc:Hexane, 1:5). The crude reaction mixture was adsorbed onto silica gel 
and purified by flash column chromatography with Pet. spirit:EtOAc (9.5:0.5 to 8:2) to yield 19 as 
an off-white solid (2.36 g, 75%). mp 105 oC;  1H NMR (500 MHz, CDCl3): δ 3.75 (s, 3H), 3.94 (s, 
3H), 6.63 (s, 1H), 7.15 (appt, J = 7.5 Hz, 1H), 7.26 (appt, J = 7.5 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 
7.58 (d, J = 8.5 Hz, 2H), 7.64 (d, J = 7.5 Hz, 1H), 8.12 (d, J = 9.8 Hz, 2H); 13C NMR (125 MHz, 
(CDCl3): δ 31.3, 52.1, 102.8, 109.7, 120.1, 120.7, 122.2, 127.8, 128.9, 129.2, 129.7, 137.2, 138.6, 
140.1, 166.7; ESI-MS m/z Calc for  C17H16NO2 [M+H
+] 266.1181; observed 266.1173. 
 
(4-(1-methyl-1H-indol-2yl)phenyl)methanol 20 
 To a stirred solution of 19 (250 mg, 0.94 mmol) in anhydrous THF was added LiAlH4 (34 mg, 0.94 
mmol) and the temperature gently raised to 40 oC. Another 3-4 eq of LiAlH4 was added in portions 
over 20-30 min and the reaction mixture was stirred at 40 oC for a further 3-4 h. The reaction was 
monitored by TLC (EtOAc: Pet. spirit, 2:3) and upon completion was slowly quenched by dropwise 
addition of saturated aqueous NH4Cl. After cessation of bubbling the mixture was diluted with 
water and extracted with EtOAc (3 x 10 mL). The organic layer was dried over anhydrous MgSO4 
and concentrated in vacuo to yield 20 as an off-white solid (190 mg, 85%). mp 97-99 oC; 1H NMR 
(500 MHz, (CD3)2SO): δ 3.71 (s, 3H), 4.72 (s, 2H), 6.54 (s, 1H), 7.13 (appt, J = 7.5 Hz, 1H), 7.24 
(appt, J = 15.5 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.5 Hz, 2H), 
7.62 (d, J = 8.0 Hz, 1H); 13C NMR (125 MHz, (CD3)2SO): δ  31.1, 64.9, 101.6, 109.5, 119.8, 120.4, 
121.6, 127.0, 127.9, 129.4, 132.1, 138.3, 140.4, 141.2; ESI-MS m/z Calc for C16H16NO [M+H
+] 
238.1232; observed 238.1224. 
 
2-(4-chloromethyl)phenyl)-1-methyl-1H-indole 21 
A solution of alcohol 20 (300 mg, 1.26 mmol) in CCl4:CH2Cl2 (1:2, 7 mL) was stirred for 10 min at 
room temperature. PPh3 (991 mg, 3.78 mmol) was then added and stirring continued for 1 h. TLC 
analysis (EtOAc:hexane, 1:4) indicated complete consumption of the alcohol. The product was 
filtered over a neutral alumina bed and washed with dichloromethane (3 x 5 mL). The combined 
filtrates were concentrated in vacuo, ensuring the water bath temperature stays below 40 o C. The 
residue obtained was triturated with pentane (3 x 4 mL) to afford crude 21 (210 mg, 65%). The 
crude 21 was used immediately and due to its instability was unable to be characterised. 
 
 
 
MIC, Checkerboard, Uptake and C. elegans experiments 
MIC, checkerboard and uptake measurements with 8325-4 wild-type, K1758 norA-knockout and 
K2378 NorA overexpressing S. aureus cells were obtained using the published methods.[2,9,10] MIC 
measurements with S. aureus MW2 and E. faecalis MMH594 were obtained as follows. Cultures of 
S. aureus MW2 and E. faecalis MMH594 were grown overnight in TSB or BHI broth, respectively, 
to stationary phase at 37°C with aeration. The cultures were diluted to an approximate density of 2 
x 10-4 CFU/mL in the appropriate worm infection media. 12.5 µL of the bacterial culture dilutions 
were inoculated into 384-well plates containing 2-fold serial dilutions (in infection media) of the 
compounds being tested. Plates were incubated at 37°C for 15 h and scored by eye for bacterial 
growth. Checkerboard MIC experiments with MW2 and MMH594 were carried out in a similar 
manner as the MIC experiments with individual compounds as described above, with the exception 
that 2-fold serial dilutions of two compounds were arrayed in the 384-well plates in such a way that 
all combinations of dilutions between the two compounds were tested.  
The C. elegans/MRSA MW2 live infection experiments were carried out according to our 
recently published methods.[18] The C. elegans/E. faecalis MMH594 experiments were carried out 
using the published procedure[19] with minor modifications. Briefly, a synchronous population of 
glp-4(bn2); sek-1(km4) worms were grown to the young adult stage on SK agar plates with E. coli 
HB101 lawns. The worms were washed off the HB101 SK plates and transferred onto BHI agar 
plates with E. faecalis MMH594 lawns and incubated for 15 h at 15°. Following infection, worms 
were resuspended in M9 and dispensed using a COPAS BioSort large particle sorter (Union 
Biometrica) into 384-well assay plates that contained compounds in 55 μl of infection assay media. 
Total volume per well was 70 µl with the final concentrations of components being 20% BHI, 60% 
M9 buffer, 19% sheath solution (Union Biometrica), 80 µg/ml kanamycin, 62.5 U/ml nystatin, and 
1% DMSO. The plates were sealed with gas-permeable membranes and incubated at 26.3° with 
85% relative humidity (RH) for 5 days without agitation.  After 5 days, the plates were washed 5 
times using a Biotek ELx405 plate washer, and Sytox Orange (Invitrogen) was added to a final 
concentration of 0.7μM. The plates were sealed with gas permeable membranes and incubated at 
20°, 80% RH for 16 h. After staining, bright field and red fluorescence images of the wells were 
captured using the ImageXpress Micro (Molecular Devices) and worm death was scored from the 
images using the image analysis software CellProfiler (www.cellprofiler.com). 
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